| Primary | Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12. | Percentage of patients who achieved glycemic target of HbA1c ≤ 7.0% with minimal weight gain (≤ 1 Kg) at month 12. | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes. | Posted | | Number | 95% Confidence Interval | percentage of patients | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00035.0(30.32 to 39.93)
- OG00115.8(12.39 to 19.73)
|
|
| |
| Secondary | Changes in HbA1c From Baseline to Month 12 | Changes in HbA1c from Baseline to Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes. | Posted | | Mean | Standard Deviation | percent | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Fasting Blood Glucose From Baseline to Month 12 | Changes in Fasting Blood Glucose From Baseline to Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients With HbA1c Reduction From Baseline >= 1.0% at Month 12 | Percentage of Patients with HbA1c Reduction from Baseline >= 1.0% at Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients Achieving HbA1c Concentration <=7.0% at Month 12 | Percentage of Patients Achieving HbA1c Concentration <=7.0% at Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 12 | Percentage of Patients Achieving HbA1c Concentration <6.5% at Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Weight From Baseline to Month 12 | Changes in Weight From Baseline to Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | kg | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients Achieving a Weight Decrease >=3% Between Baseline and Month 12 | Percentage of Patients Achieving a Weight Decrease >=3% between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients Achieving a Weight Decrease >=5% Between Baseline and Month 12 | Percentage of Patients Achieving a Weight Decrease >=5% between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Fasting Total Cholesterol Between Baseline and Month 12 | Changes in Fasting Total Cholesterol Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Fasting HDL Between Baseline and Month 12 | Changes in Fasting HDL Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Fasting LDL Between Baseline and Month 12 | Changes in Fasting LDL Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Fasting Triglycerides Between Baseline and Month 12 | Changes in Fasting Triglycerides Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Diastolic Blood Pressure Between Baseline and Month 12 | Changes in Diastolic Blood Pressure Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mmHg | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Changes in Systolic Blood Pressure Between Baseline and Month 12 | Changes in Systolic Blood Pressure Between Baseline and Month 12 | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Mean | Standard Deviation | mmHg | | Baseline, Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Percentage of Patients With Hypoglycemia Episodes Between Baseline and Month 12 | Percentage of patients with Hypoglycemia Episodes Between Baseline and Month 12. All episodes consistent with hypoglycemia with or without a confirmatory blood glucose reading were collected. | All patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline, and analyses were conducted irrespective of later treatment changes | Posted | | Number | | percentage of patients | | Baseline to Month 12 | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. exenatide : subcutaneous injection, 5mcg or 10mcg, twice a day | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Factors of Gender, Baseline Presence of Medical Conditions, and Previous Gastrointestinal Symptoms Associated With Treatment Choice at Baseline | Number of patients per arm who were evaluated in 3 factors at baseline (gender, presence of medical conditions, and previous gastrointestinal symptoms) were analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. | All patients consented to release information; fulfilled study entry criteria. Analyses conducted on baseline arm assignment, irrespective of later treatment changes. Only those assigned to an arm were included. Missing values for numeric covariates replaced with means; categorical ones, with modes. | Posted | | Number | | participants | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
|
| Secondary | Factor of 1 Percent (%) Higher Baseline HbA1c Associated With Treatment Choice at Baseline | Factor of 1% higher baseline HbA1c (from most recent HbA1c) was analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. HbA1c was measured as a percent of normal (%). | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. FAS=444, however 1 patient in the exenatide arm was missing data for the most recent HbA1c at baseline so n=443. | Posted | | Mean | Standard Deviation | Percentage of normal | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
|
| Secondary | Factor of Longer Duration of Diabetes Associated With Treatment Choice at Baseline | The Factor of longer duration of diabetes at baseline (diagnosed 1 year longer) was analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. Duration of diabetes was measured in years since the date of diabetes diagnosis. | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. | Posted | | Mean | Standard Deviation | years | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
|
| Secondary | Factor of Older Age Associated With Treatment Choice at Baseline | Older age (1 year older) was analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. Age was measured in years. | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. | Posted | | Mean | Standard Deviation | years | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
| |
| Secondary | Factor of Higher Body Mass Index (BMI) Associated With Treatment Choice at Baseline | Factor of higher body mass index (BMI) (1 kilogram per meter squared (kg/m^2) higher) was analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. BMI measured as kg/m^2. | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. FAS for basal insulin arm=438 but one patient did not have data in this arm so n=437. | Posted | | Mean | Standard Deviation | kg/m^2 | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
|
| Secondary | Factor of Greater Height Associated With Treatment Choice at Baseline | Factor of greater height (1 centimeter higher) was analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. Height was measured in centimeters (cm) . | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. FAS for basal insulin arm=438 but one patient did not provide height data so n=437. | Posted | | Mean | Standard Deviation | cm | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. basal insulin : subcutaneous injection, dosing according to physician's clinical judgment |
|
| Secondary | Factors of Higher Creatinine, Higher Fasting High Density Lipoprotein (HDL) Cholesterol, Higher Fasting Cholesterol, and Higher Fasting Triglycerides Which Were Associated With Treatment Choice at Baseline | Factors of higher creatinine: 1 milligram per deciliter higher (mg/dL) and higher fasting lipids (HDL cholesterol: 1 mg/dL higher; total cholesterol: 1 mg/dL higher; triglycerides: 1 mg/dL higher) were analyzed for association with treatment choice at baseline. A total of 12 factors were evaluated. A multivariate logistic regression model using the full analysis set (FAS) population was performed for each of the factors to determine if exenatide treatment was more likely to be initiated in the presence of the specific factor. Creatinine and fasting lipids were measured in milligrams per deciliter (mg/dL). | Full analysis set (FAS) population: all patients who provided consent to release information and who fulfilled the study entry criteria. FASS=444 and 438 in each arm respectively but the number of patients with creatinine and fasting lipids data at baseline varied. N is presented with each category. | Posted | | Mean | Standard Deviation | mg/dL | | baseline | | | | ID | Title | Description |
|---|
| OG000 | Exenatide | The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. Exenatide subcutaneous injection, 5mcg or 10mcg, twice a day. | | OG001 | Basal Insulin |
|